Boston Scientific (NYSE:BSX) Price Target Lowered to $100.00 at Oppenheimer

Boston Scientific (NYSE:BSX) had its target price dropped by Oppenheimer from $125.00 to $100.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the medical equipment provider’s stock. Oppenheimer’s target price indicates a potential upside of 11.12% from the company’s current price.

Other analysts also recently issued reports about the company. Citigroup reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday. Barclays lifted their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. UBS Group reissued a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Cowen restated a “buy” rating on shares of Boston Scientific in a research report on Thursday, December 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Boston Scientific in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $123.89.

Boston Scientific Stock Down 4.0%

BSX stock opened at $90.00 on Friday. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The company’s 50-day moving average price is $97.14 and its 200 day moving average price is $100.46. Boston Scientific has a 52 week low of $85.98 and a 52 week high of $109.50. The company has a market cap of $133.41 billion, a P/E ratio of 48.13, a P/E/G ratio of 1.66 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same period last year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts expect that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 93,095 shares of company stock valued at $9,305,450 over the last 90 days. Insiders own 0.50% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently added to or reduced their stakes in BSX. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Sound Income Strategies LLC increased its position in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the last quarter. Steph & Co. purchased a new position in Boston Scientific during the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp boosted its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. Finally, Financial Consulate Inc. purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at $25,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands cardiovascular/neurovascular footprint — the Penumbra deal gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular markets, which management says accelerates long-term growth and product leadership. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Analyst/product catalysts support upside — analysts cite recent approvals (Farapoint PFA) and product wins as reinforcing BSX’s procedure-led growth story and a maintained buy rating from at least one firm. Boston Scientific: Farapoint PFA Approval Strengthens EP Ecosystem and Supports Buy Rating
• Positive Sentiment: Ongoing product & small-M&A pipeline — recent moves like the Valencia Technologies agreement (eCoin ITNS) plus CE mark wins and facility expansion support incremental revenue diversification beyond the core CV business. BSX Stock May Gain From Newly Inked Deal to Buy Valencia Technologies
• Neutral Sentiment: Deal structure & size disclosed — the transaction is a cash-and-stock deal valued at roughly $14.5B (enterprise value); full financial impact (financing, dilution, synergies) will drive near-term guidance updates and investor reaction. Boston Scientific to buy Penumbra in deal valued at $14.5 billion
• Negative Sentiment: Immediate market reaction: shares fell on concerns about deal size, near-term dilution and integration risk; Penumbra shares jumped. Large put-option buying also signaled hedging/bearish bets, amplifying downward pressure. Boston Scientific to acquire Penumbra in $14.5B deal
• Negative Sentiment: Critical commentary and legal risk flags — some analysts and commentators questioned the price and strategic fit, and a shareholder-lawyer bulletin referencing Penumbra investigations could create incremental legal/transactional scrutiny. Boston Scientific’s Bet On Penumbra Isn’t To My Liking Boston Scientific Acquiring Penumbra Was The Logical Next Step BRODSKY & SMITH SHAREHOLDER UPDATE

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.